Floatz logo

SIMVASTATIN

Smith-Lemli-Opitz Syndrome

Oregon Health and Science UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Smith-Lemli-Opitz Syndrome cohort.

Asset / SponsorPhaseRating
Cholesterol Suspension
University of Colorado, Denver
Phase 2BB
CHOLALIC ACID
University of Nebraska
Phase 1/2CCC
Lovastatin
Northwestern University
Phase 2CC
Crh
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
D

Same molecule, other indications

SIMVASTATIN is also rated in:

HypercholesterolemiaDormant
BBB
Indicative ·
76 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
75 / 100
View asset →
inherited lipid metabolism disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →